Session » Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2488

A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2524

Achievement of Imaging Remission Among Patients with Rheumatoid Arthritis in Clinical Remission and Their Characteristics

9:00AM-11:00AM: Abstract Number: 2539

Analysis of Joints Susceptible to Rheumatoid Arthritis (RA) and Their Recovery Sequence Based on DAS28 and Physical Function Based on HAQ with Smart System of Disease Management (SSDM) in China：a Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 2533

Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?

9:00AM-11:00AM: Abstract Number: 2507

Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate

9:00AM-11:00AM: Abstract Number: 2468

Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2463

Association Between High Sodium Intake and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2497

Associations Between Dietary Intake of Vitamin D, Omega-3 Fatty Acids, Folate and EULAR Response in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2554

Changes in Blood Pressure Following the Initiation of Disease Modifying Therapies in US Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2529

Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2464

Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2538

Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis

9:00AM-11:00AM: Abstract Number: 2516

Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2473

Concordance Between the Patient, Nurse and Physician Assessment of Clinical Outcomes in a Cohort of Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 2485

Correlates of Successful Flare Management: The Role of Clinician-Driven Treatment, Home-Based Strategies, and Medication Change

9:00AM-11:00AM: Abstract Number: 2465

Discordance Between Tender and Swollen Joint Count and Patient’s and Evaluator’s Global Assessment May Reduce Likelihood of Remission in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2496

DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center

9:00AM-11:00AM: Abstract Number: 2514

Does Combination of Conventional Synthetic Disease Modifying Antirheumatic Drug with Anti-TNF Influence the Long Term Retention Compared to Anti-TNF Monotherapy in Psoriatic Arthritis? an Analysis from Rhumadata® over 12 Years

9:00AM-11:00AM: Abstract Number: 2480

Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis

9:00AM-11:00AM: Abstract Number: 2527

Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors

9:00AM-11:00AM: Abstract Number: 2472

Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort

9:00AM-11:00AM: Abstract Number: 2486

Effect of a Dynamic Exercise Program in Combination with a Mediterranean Diet in Strength, Joint Mobility and Disease Activity in Women with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2549

Effect of Interleukin-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type 9 Serum Levels in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2535

Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2555

Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2544

Glucocorticoid Treatment for 12 Weeks in Early Rheumatoid Arthritis Is Related to an Increase in BMI

9:00AM-11:00AM: Abstract Number: 2541

Glucocorticoid Use and Low Thoracic Bone Mineral Density Are Predictors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study

9:00AM-11:00AM: Abstract Number: 2537

High Retention Rates and Clinical Efficacy of Tocilizumab As First-Line Biologic Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2462

Higher Number of Tender Than Swollen Joint Count Is Associated to Higher Patient Reported Outcomes and Composite Scores As Well As Reduced Probability of Obtaining Remission: Results from a One-Year Follow-up Study of Established RA Patients Starting Bdmards

9:00AM-11:00AM: Abstract Number: 2469

How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed

9:00AM-11:00AM: Abstract Number: 2461

Identifying Flare in Rheumatoid Arthritis: What Is the Threshold?

9:00AM-11:00AM: Abstract Number: 2475

Identifying Key Variables for Inclusion in a Smartphone App to Support Clinical Care and Research in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2543

Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World

9:00AM-11:00AM: Abstract Number: 2551

Impact of Multmorbidity on Disability and Disease Activity over Time in Patients with RA Taking Biologics: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2490

Impact of Obesity Activity Indices and Therapeutic Dosage in Patients with Rheumatoid Arthritis in Dominican Republic

9:00AM-11:00AM: Abstract Number: 2531

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Functional and Clinical Outcomes Among Patients with Rheumatoid Arthritis: Passion Study

9:00AM-11:00AM: Abstract Number: 2478

Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort

9:00AM-11:00AM: Abstract Number: 2504

Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept

9:00AM-11:00AM: Abstract Number: 2509

Implementation of the Treat to Target Concept in Evaluation of Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2487

In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare

9:00AM-11:00AM: Abstract Number: 2481

Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2518

Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time

9:00AM-11:00AM: Abstract Number: 2491

Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?

9:00AM-11:00AM: Abstract Number: 2489

Joint Damage Appears As Severe As Inflammation According to Physician Visual Analog Scales in Patients with Rheumatoid Arthritis Regardless of Disease Severity at 2 Sites, Which May Limit Results of a Treat-to-Target Strategy

9:00AM-11:00AM: Abstract Number: 2550

Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients

9:00AM-11:00AM: Abstract Number: 2482

Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate

9:00AM-11:00AM: Abstract Number: 2517

Long-Term Stability of the 5-Item Compliance Questionnaire Rheumatology As a Measure of Adherence in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2511

Longitudinal Observation of Disease Activity and Treatment of Rheumatoid Arthritis Who Developed Methotrexate-Associated Lymphoproliferative Disorders

9:00AM-11:00AM: Abstract Number: 2521

Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients

9:00AM-11:00AM: Abstract Number: 2513

Maintained Remission in Rheumatoid Arthritis over 7 Years in «Real Life Conditions» : A Monocentric Observational Study

9:00AM-11:00AM: Abstract Number: 2503

Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study

9:00AM-11:00AM: Abstract Number: 2532

Methotrexate Adherence in an Online Network of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2492

Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’

9:00AM-11:00AM: Abstract Number: 2520

Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab

9:00AM-11:00AM: Abstract Number: 2493

Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab

9:00AM-11:00AM: Abstract Number: 2525

Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2530

Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance

9:00AM-11:00AM: Abstract Number: 2515

Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)

9:00AM-11:00AM: Abstract Number: 2474

Patients’ Experiences of Using a Smartphone App for Remote Monitoring of Rheumatoid Arthritis, Integrated into the Electronic Medical Record, and Its Impact on Consultations

9:00AM-11:00AM: Abstract Number: 2476

Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)

9:00AM-11:00AM: Abstract Number: 2522

Pharmacomicrobiomics of Methotrexate: Baseline Intestinal Microbiota Correlates with Therapeutic Response

9:00AM-11:00AM: Abstract Number: 2545

Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2460

Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort

9:00AM-11:00AM: Abstract Number: 2552

Predictive Value of Chest HRCT Patterns for Respiratory Adverse Event Among RA Patients Treated with Biological Therapy: Long-Term Results from an Observational Study

9:00AM-11:00AM: Abstract Number: 2519

Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 2528

Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study

9:00AM-11:00AM: Abstract Number: 2553

Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database

9:00AM-11:00AM: Abstract Number: 2500

Prevalence of Sustained Remission in Patients with Rheumatoid Arthritis in Sweden. Impact of Criteria Sets and Early Treatment, a Nationwide Register Study in Sweden

9:00AM-11:00AM: Abstract Number: 2547

Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2501

Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort

9:00AM-11:00AM: Abstract Number: 2534

Radiographic Remission in Patients with Seropositive RA at Ten Years after Diagnosis, Treated in a Real Life Setting

9:00AM-11:00AM: Abstract Number: 2484

Real World Treat to Target Strategy in Rheumatoid Arthritis: Radiograph and MRI Outcomes in Three Cohorts with 18 Month Follow up

9:00AM-11:00AM: Abstract Number: 2523

Reasons for Provider Non-Adherence to a Treat to Target Strategy in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2510

Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2542

Reducing the Dosage of Glucocorticoid to Zero Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study

9:00AM-11:00AM: Abstract Number: 2466

Remission According to RAPID3 (routine assessment of patient index data 3) in Patients with Rheumatoid Arthritis: A Cross-Sectional 3 Center Study from Routine Care

9:00AM-11:00AM: Abstract Number: 2483

Results of a Pilot Study of a Tailored Symptom Assessment Tool to Enhance Patient-Centered Care in Rheumatoid Arthritis: Choice RA

9:00AM-11:00AM: Abstract Number: 2512

Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden

9:00AM-11:00AM: Abstract Number: 2506

Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy

9:00AM-11:00AM: Abstract Number: 2477

Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2508

Significant Improvement of Rheumatoid Arthritis (RA) Outcome with Repeat Application of Disease Management (SSDM) Mobiles Tools: A Cohort Study of RA Patients in China

9:00AM-11:00AM: Abstract Number: 2548

Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings

9:00AM-11:00AM: Abstract Number: 2498

Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2494

The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept

9:00AM-11:00AM: Abstract Number: 2540

The Longitudinal Impact of Biologic Use on Disability within a RA Registry

9:00AM-11:00AM: Abstract Number: 2536

The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2495

The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2505

Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2526

TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse

9:00AM-11:00AM: Abstract Number: 2499

Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2502

Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms

9:00AM-11:00AM: Abstract Number: 2470

Treat to Target: Theoretical Agreement Vs Daily Applicability

9:00AM-11:00AM: Abstract Number: 2546

Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer

9:00AM-11:00AM: Abstract Number: 2467

Validation of the FLARE Questionnaire for the Detection of a Disease Flare in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2471

What Are the Reasons of Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity and What Is the Impact of This Discordance on Remission, Function and Structure at 1 Year?

9:00AM-11:00AM: Abstract Number: 2479

Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].